Clinical study table 24, table 25, page 41. In colorectal cancer, N=90, ORR rises from 36% to 46%. But Duration of Responses rises from 1.6 months to 22 months.
Other cancers were studied - in total 59, of which 14 endometrial, 11 biliary, 9 gastric, etc. Many cases were studied N of 1. There were variable but meaningful increases in ORR but big increases in DOR.
Click to enlarge.
For the Keytruda discussion in a December 2017 article on precision medicine in Nat Rev Clin Onc, by Moscow, Fojo & Schilsky (NCI, Columbia, ASCO), see here and clipping below.
|click to enlarge|
The December 21, 2017 NEJM has an interesting letter from Yarchoan and colleagues at Johns Hopkins plotting three things together: ORR, TMB, and Tumor Type in one graphic.